HeartMate App-Based Remote Monitoring for Cardiovascular Risk Factor Management
- Sponsor
- Yonsei University
- Study ID
- NCT07721584
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Cardiac Rehabilitation
- Cardiovascular Diseases
- Cardiovascular Risk Factor
- Coronary Artery Disease
- Heart Failure, Systolic
- Heart Valve Diseases
- Peripheral Arterial Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- HeartMate App-Based Remote Cardiac Rehabilitation Program — DEVICEA 6-week smartphone application program delivering a daily heart check using remote photoplethysmography (rPPG), aerobic and resistance exercise, breathing training, and a cognitive-behavioral mind program. Trained staff provide message-based counseling and exercise/lifestyle guidance at least weekly, and the Severance research team reviews monitoring logs at least weekly and handles all medical decisions and adverse events.
- Usual Care with HeartMate App-Based rPPG Measurement Only — DEVICEStandard outpatient follow-up and lifestyle education materials without the exercise or mind program. The HeartMate app is installed solely for rPPG-based digital-biomarker measurement at baseline and at 6 weeks, ensuring identical measurement conditions across groups.
Study Details
This exploratory pilot randomized controlled trial evaluates whether a HeartMate application-based remote patient monitoring (RPM) and digital cardiac rehabilitation program improves cardiovascular, functional, and psychological outcomes in patients with cardiac disease. A total of 200 participants with cardiovascluar disease requiring rehabilitation are randomly assigned in a 1:1 ratio to an intervention group or a control group. The intervention group uses the HeartMate app-based remote cardiac rehabilitation program for 6 weeks, including a daily heart check using smartphone remote photoplethysmography (rPPG), aerobic and resistance exercise, breathing training, and a cognitive-behavioral 'mind' program, with weekly remote coaching. The control group receives usual outpatient care and lifestyle education materials, with the app installed only for rPPG measurement so that digital-biomarker measurement is identical across groups. Clinical assessments (6-minute walk distance, grip strength, blood pressure, blood lipids and metabolic markers), questionnaires (SF-12, PHQ-9, GAD-7, KOSS-24), and digital biomarkers (rPPG-derived heart rate, heart rate variability, respiration, activity) are collected at baseline and at 6 weeks. The primary outcome is the between-group difference in the change in 6-minute walk distance from baseline to 6 weeks. Because this is an exploratory pilot, the results are intended to estimate the effect size and variance for a future definitive randomized controlled trial, and to assess the validity of digital biomarkers as well as the safety, feasibility, and adherence of the program.
Key Dates
- First listed
- Jul 23, 2026
- Start date
- Jul 14, 2026
- Status verified
- Jul 2026
- Primary completion
- Jun 30, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Intervention Group (HeartMate App-Based Remote Cardiac Rehabilitation)Participants use the HeartMate app-based remote cardiac rehabilitation program for 6 weeks (daily rPPG heart check; aerobic and resistance exercise; breathing training; cognitive-behavioral mind program), with at least weekly remote coaching.
- Placebo Comparator: Control Group (Usual Care with App-Based Measurement Only)Participants receive usual outpatient follow-up and lifestyle education materials. The HeartMate app is installed for rPPG-based measurement only (no exercise or mind program) to keep digital-biomarker measurement identical across groups.
Primary Outcome Measure
Change from Baseline in 6-Minute Walk Test (6MWT) Distance at 6 Weeks [ Time Frame: Baseline and 6 weeks (change from baseline to Week 6) ]
Central Contacts
- Chan Joo Lee, Professor+82-2-2228-8460
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial DiseasePHASE1/PHASE2 · Not Yet Recruiting · Venturis Therapeutics, Inc. · Chicago, Illinois
- Cardiovascular BiorepositoryRecruiting · Kenneth S. Campbell · Lexington, Kentucky
- Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem CellsEnrolling By Invitation · Scripps Translational Science Institute · La Jolla, California